Drug Trial Radar · NCT07499037
Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO
Last checked: Nov 20, 2026Latest source record: Apr 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 2027
Primary completion
Sep 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- University Hospital OstravaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University Hospital, Motol
- First posted
- Mar 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The standard and most common therapy is anticoagulation with heparin according to activated partial thromboplastin time (aPTT) during extracorporeal membrane oxygenation (ECMO) support. The study will focus on evaluating the efficacy and safety of new anticoagulants on ECMO, namely argatroban and enoxaparin in lower doses controlled according to targeted antiIIa and antiXa markers.
Conditions
- Pneumonia
- Heart Failure
Interventions
Low anticoagulation dose of argatroban and enoxaparin during ECMODrug
Study subjects in this group will receive low anticoagulation dose of argatroban and enoxaparin during ECMO
Standard anticoagulation dose of argatroban and enoxaparin during ECMODrug
Study subjects in this group will receive standard anticoagulation dose of argatroban and enoxaparin during ECMO
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of bleeding complicationsTime frame: During ECMO, up to 4 weeks
- Safety of thrombotic complicationsTime frame: During ECMO, up to 4 weeks
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
University Hospital Motol
Prague, Czechia
University Hospital Ostrava
Ostrava, Moravian-Silesian Region, Czechia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.